ImmunoGen Inc. (IMGN)’s Financial Results Comparing With Dare Bioscience Inc. (NASDAQ:DARE)

ImmunoGen Inc. (NASDAQ:IMGN) and Dare Bioscience Inc. (NASDAQ:DARE) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoGen Inc. 53.82M 15.13 167.87M -1.03 0.00
Dare Bioscience Inc. N/A 0.00 22.95M -2.92 0.00

Table 1 highlights ImmunoGen Inc. and Dare Bioscience Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents ImmunoGen Inc. (NASDAQ:IMGN) and Dare Bioscience Inc. (NASDAQ:DARE)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
ImmunoGen Inc. -311.91% -684.8% -43.8%
Dare Bioscience Inc. 0.00% -180.3% -166.4%

Risk and Volatility

ImmunoGen Inc. has a beta of 2.53 and its 153.00% more volatile than S&P 500. Competitively, Dare Bioscience Inc.’s beta is 2.23 which is 123.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of ImmunoGen Inc. are 4.6 and 4.6 respectively. Its competitor Dare Bioscience Inc.’s Current Ratio is 8.5 and its Quick Ratio is 8.5. Dare Bioscience Inc. can pay off short and long-term obligations better than ImmunoGen Inc.

Insider & Institutional Ownership

Institutional investors owned 85.6% of ImmunoGen Inc. shares and 21.3% of Dare Bioscience Inc. shares. Insiders owned 0.1% of ImmunoGen Inc. shares. Insiders Competitively, owned 1.2% of Dare Bioscience Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ImmunoGen Inc. -2.36% -12.8% -43.19% -43.49% -11.07% -16.07%
Dare Bioscience Inc. -4.87% -9.89% -18% -44.59% -66.67% -62.11%

For the past year ImmunoGen Inc.’s stock price has smaller decline than Dare Bioscience Inc.

Summary

On 5 of the 9 factors ImmunoGen Inc. beats Dare Bioscience Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.